权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bacteriophages against surgical site infections

噬菌体对抗手术部位感染

基本信息

批准号：
10070793
负责人：
金额：
$ 253.76万
依托单位：
OXFORD SILK PHAGE TECHNOLOGIES LIMITED
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10070793
关键词：
Bacteriophages against surgical site infections

项目摘要

Oxford Silk Phage Technologies (OSPT) is developing a disruptive platform technology using bacteriophages to actively prevent medical device and implant infections, a growing concern in the current context of global threatening antimicrobial resistance.Building upon its proof-of-concept work, OSPT will use its bacteriophage bio-textile technology to design and produce a disruptive, non-toxic device actively preventing infections and migration of the most problematic bacteria within wounds. The prototype equipment developed in previous OSPT grants to manufacture the material will here be upscaled to increase continuous production yield for this project and ahead of clinical trial production needs. The lower risk first product will be a stepping-stone for subsequent implantable and more challenging application of OSPT's technology.Collaboration of two bacteriophage expert academic groups at Exeter and Hertfordshire universities will be critical in isolating, selecting and characterising bacteriophages against 4 major drug-resistant pathogens. In parallel, the academic collaborators will develop strategies the render GMP production of phages more cost-effective, significantly reducing future manufacturing costs. Hertfordshire university will also adapt an ex-vivo model of skin to optimise and test the devices ahead of final biological evaluations, which will take the project to clinical trial phase readiness.The final delivery will be prototype devices successfully tested, with a clinical trial dossier and plan for GMP production at IUK-CPI's new microbiome centre.

Oxford Silk Phage Technologies（OSPT）正在开发一种颠覆性的平台技术，利用噬菌体积极预防医疗器械和植入物感染，在当前全球威胁抗生素耐药性的背景下，这一问题日益受到关注。在其概念验证工作的基础上，OSPT将利用其噬菌体生物纺织品技术设计和生产一种颠覆性的，无毒装置，有效防止感染和伤口内最有问题的细菌的迁移。在之前的OSPT赠款中开发的用于制造材料的原型设备将在这里进行升级，以提高该项目的连续生产产量，并提前满足临床试验生产需求。风险较低的第一个产品将成为OSPT技术后续植入式和更具挑战性应用的垫脚石。埃克塞特和赫特福德郡大学的两个噬菌体专家学术小组的合作将在分离，选择和表征针对4种主要耐药病原体的噬菌体方面发挥关键作用。与此同时，学术合作者将制定策略，使GMP生产更具有成本效益，大大降低未来的制造成本。赫特福德郡大学还将采用一种离体皮肤模型，在最终生物学评估之前对设备进行优化和测试，这将使该项目进入临床试验阶段准备就绪。最终交付的将是经过成功测试的原型设备，以及临床试验档案和在IUK-CPI新微生物组中心进行GMP生产的计划。